Thomas McNerney & Partners

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

SG Biofuels is an integrated bioenergy crop company specializing in the development and production of elite hybrid seeds of Jatropha, a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. Leveraging the largest and most diverse library of Jatropha genetic material, the company utilizes molecular breeding and biotechnology to optimize its offerings. SG Biofuels combines advanced scientific research with expertise in agronomy and plantation management to capitalize on the potential of Jatropha. The company has received multiple accolades, including recognition as one of the Top 5 Renewable Jet Fuel Supply Chain Companies and one of the Top 50 Companies in Bioenergy for several consecutive years. Additionally, it has been honored with awards for its contributions to feedstock domestication and sustainability within the biofuel sector.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

AxioMed LLC specializes in designing and developing disc replacement devices aimed at alleviating neck pain and restoring normal spinal functions for patients suffering from degenerative disc disease. Founded in 2001 and based in Malden, Massachusetts, the company was previously known as AxioMed Spine Corporation until its name change in 2014. AxioMed has developed the Freedom® Lumbar Disc and initiated clinical trials for its products, which are intended to improve the standard of care beyond traditional fusion and first-generation artificial discs. The company is led by CEO Patrick McBrayer and COO James Kuras, who oversee a team with extensive experience in spinal implants and engineering. They are supported by a Medical Advisory Panel of surgeons from prominent spine centers and universities. AxioMed's operations encompass product development, testing, clinical and regulatory affairs, and manufacturing, with ongoing projects focusing on cervical spine solutions.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for pruritus and gastrointestinal diseases. The company's lead product, Asimadoline, is an orally active kappa opioid receptor agonist that targets itching associated with atopic dermatitis and also addresses gastrointestinal conditions such as irritable bowel syndrome and functional dyspepsia. Founded in 2005, Tioga aims to provide effective treatments that offer safety benefits by minimizing typical opioid side effects, thus enhancing patient outcomes in managing these conditions.

SG Biofuels is an integrated bioenergy crop company specializing in the development and production of elite hybrid seeds of Jatropha, a low-cost feedstock for biodiesel, bio-jet fuel, and specialty chemicals. Leveraging the largest and most diverse library of Jatropha genetic material, the company utilizes molecular breeding and biotechnology to optimize its offerings. SG Biofuels combines advanced scientific research with expertise in agronomy and plantation management to capitalize on the potential of Jatropha. The company has received multiple accolades, including recognition as one of the Top 5 Renewable Jet Fuel Supply Chain Companies and one of the Top 50 Companies in Bioenergy for several consecutive years. Additionally, it has been honored with awards for its contributions to feedstock domestication and sustainability within the biofuel sector.

InnoPharma, LLC, founded in 2005 and located in Piscataway, New Jersey, is a privately held pharmaceutical research and development company. The firm specializes in the development of complex generic and innovative specialty pharmaceutical and biopharmaceutical products, particularly in injectable and ophthalmic dosage forms. InnoPharma boasts a diverse portfolio of products under development, employing a range of formulations such as suspensions, lyophilized products, emulsions, liposomes, micelles, and lipid complexes.

CAS Medical Systems is dedicated to the design and manufacture of innovative, non-invasive technologies and products vital to patient care in the most challenging clinical environments. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

AxioMed LLC specializes in designing and developing disc replacement devices aimed at alleviating neck pain and restoring normal spinal functions for patients suffering from degenerative disc disease. Founded in 2001 and based in Malden, Massachusetts, the company was previously known as AxioMed Spine Corporation until its name change in 2014. AxioMed has developed the Freedom® Lumbar Disc and initiated clinical trials for its products, which are intended to improve the standard of care beyond traditional fusion and first-generation artificial discs. The company is led by CEO Patrick McBrayer and COO James Kuras, who oversee a team with extensive experience in spinal implants and engineering. They are supported by a Medical Advisory Panel of surgeons from prominent spine centers and universities. AxioMed's operations encompass product development, testing, clinical and regulatory affairs, and manufacturing, with ongoing projects focusing on cervical spine solutions.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

Celator Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company specializes in creating optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Celator's product pipeline includes VYXEOS, a liposomal formulation of irinotecan and floxuridine, currently undergoing Phase III clinical trials for acute myeloid leukemia (AML). Additionally, CPX-351, another liposomal formulation of cytarabine and daunorubicin, is also in Phase III studies for AML. CPX-1, a combination of irinotecan and floxuridine, has completed Phase II trials targeting colorectal cancer. The company also has a preclinical candidate, CPX-8, which is a nanoparticle formulation of docetaxel. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.

Altair Therapeutics was a biopharmaceutical company that focused on developing therapeutics to treat human respiratory diseases.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Virdante Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of drugs for autoimmune and inflammatory diseases. Founded in 2007 and previously known as Centaurus Pharmaceuticals, the company specializes in creating antibody and Fc-fusion therapies aimed at addressing various autoimmune conditions. Through its innovative research and development efforts, Virdante Pharmaceuticals seeks to improve treatment options for patients suffering from these disorders.

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. It offers HYDRO 40 foam, a dry skin treatment product; tersi foam, a leave-on foam indicated for the treatment of seborrheic dermatitis and tinea versicolor; rinnovi nail system, a prescription nail system that is designed to clean, treat, and protect diseased, damaged, brittle, and ingrown nails; and cleanse and treat, a pad delivery technology system for the treatment of acne. Quinnova Pharmaceuticals, Inc. was founded in 2003 and is based in Newtown, Pennsylvania.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic liver diseases, addressing a significant unmet medical need. The company's lead product, OCR-002, functions as an ammonia scavenger and is being investigated in both intravenous and oral formulations to treat hyperammonemia. Recently, Ocera completed a Phase 2b clinical trial named STOP-HE, which assessed the safety and efficacy of intravenously administered OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and explore potential development pathways for its therapeutics.

Clarus Therapeutics is a men's health specialty pharmaceutical company based in Northbrook, Illinois, founded in 2003. The company specializes in the development and commercialization of oral testosterone replacement therapies in the United States. Its primary product, JATENZO, is a soft gel formulation of testosterone undecanoate, designed to treat men with low testosterone levels, also known as hypogonadism. JATENZO is notable for being the first and only oral testosterone replacement therapy available, serving as the sole source of revenue for Clarus Therapeutics. In addition to JATENZO, the company is also engaged in the development of other androgen-based medications for both men and women.

Tranzyme Pharma is a biopharmaceutical company based in North Carolina that specializes in the discovery, development, and commercialization of mechanism-based therapies. The company focuses on small molecule therapeutics aimed at treating acute and chronic gastrointestinal motility disorders. Tranzyme's product portfolio includes TZP-101, which is intended for the treatment of post-operative ileus and severe gastroparesis, as well as TZP-301, which targets obesity and metabolic syndrome. The company retains worldwide rights to its programs, emphasizing its commitment to addressing significant health challenges related to gastrointestinal conditions.

Leptos Biomedical specializes in a proprietary neuromodulation therapy aimed at treating chronic obesity. Established in 2002 and located in Fridley, Minnesota, the company utilizes a pacemaker-like device to electrically activate a specific nerve within the autonomic nervous system, thereby addressing obesity at a neurological level. This innovative approach seeks to offer an alternative treatment option for individuals struggling with weight management.

Softscope Medical Technologies, founded in 2003 and based in Minnetonka, Minnesota, specializes in the development of endoscopic products. The company is dedicated to creating CROS enabled devices designed to facilitate the passage of a colonoscope, as well as CROS devices for small bowel enteroscopy.

Elron Ventures is a venture capital firm based in Tel Aviv, Israel, founded in 1962. It specializes in seed and early-stage investments, focusing primarily on sectors such as enterprise software, cybersecurity, and medical technology. The firm is committed to transforming promising ideas into global industry leaders and has a notable history of successful investments and mergers and acquisitions. Elron Ventures has played a significant role in the Israeli innovation landscape, having been a founder and early investor in a variety of companies, including those in healthcare, defense, telecommunications, and medical devices. The firm's investment strategy emphasizes opportunities within Israel, reflecting its dedication to supporting local entrepreneurial talent.

Galil Medical Ltd. specializes in developing cryotherapy solutions aimed at treating various medical conditions across multiple specialties. Founded in 1996 and headquartered in Yokneam, Israel, with additional offices in Arden Hills, Minnesota, the company provides advanced cryosurgical systems that utilize compressed Argon gas to generate sub-zero temperatures for the cryosurgical ablation of both benign and cancerous tumors. Their product lineup includes the Visual-ICE system, which allows for precise control to protect critical anatomy, as well as the SeedNet and Presice systems designed for minimally invasive percutaneous procedures. Galil Medical's offerings extend to ultra-thin needles, thermal sensors, and other accessories that enhance the efficacy of their treatments. Their technologies are utilized in the management of conditions such as kidney, prostate, liver, lung, and breast cancers, among others. The company operates as a subsidiary of BTG plc, reflecting its integration into a broader healthcare framework.

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. It offers HYDRO 40 foam, a dry skin treatment product; tersi foam, a leave-on foam indicated for the treatment of seborrheic dermatitis and tinea versicolor; rinnovi nail system, a prescription nail system that is designed to clean, treat, and protect diseased, damaged, brittle, and ingrown nails; and cleanse and treat, a pad delivery technology system for the treatment of acne. Quinnova Pharmaceuticals, Inc. was founded in 2003 and is based in Newtown, Pennsylvania.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, and marketing of biopharmaceutical products. Its primary product is Myobloc (rimabotulinumtoxinB) Injection, marketed in the U.S., and NeuroBloc (Botulinum Toxin Type B) Injectable Solution, available in select international markets. This product is the only botulinum toxin type B offered to healthcare providers and patients globally and is specifically indicated for treating cervical dystonia to alleviate severe abnormal head positions and associated pain. In addition to its pharmaceutical offerings, Solstice provides reimbursement and product support services and maintains MYOBLOC University, an online platform designed to enhance physician education through self-study resources and learning technologies.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from acute and chronic liver diseases, addressing a significant unmet medical need. The company's lead product, OCR-002, functions as an ammonia scavenger and is being investigated in both intravenous and oral formulations to treat hyperammonemia. Recently, Ocera completed a Phase 2b clinical trial named STOP-HE, which assessed the safety and efficacy of intravenously administered OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and explore potential development pathways for its therapeutics.

Clarus Therapeutics is a men's health specialty pharmaceutical company based in Northbrook, Illinois, founded in 2003. The company specializes in the development and commercialization of oral testosterone replacement therapies in the United States. Its primary product, JATENZO, is a soft gel formulation of testosterone undecanoate, designed to treat men with low testosterone levels, also known as hypogonadism. JATENZO is notable for being the first and only oral testosterone replacement therapy available, serving as the sole source of revenue for Clarus Therapeutics. In addition to JATENZO, the company is also engaged in the development of other androgen-based medications for both men and women.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, and marketing of biopharmaceutical products. Its primary product is Myobloc (rimabotulinumtoxinB) Injection, marketed in the U.S., and NeuroBloc (Botulinum Toxin Type B) Injectable Solution, available in select international markets. This product is the only botulinum toxin type B offered to healthcare providers and patients globally and is specifically indicated for treating cervical dystonia to alleviate severe abnormal head positions and associated pain. In addition to its pharmaceutical offerings, Solstice provides reimbursement and product support services and maintains MYOBLOC University, an online platform designed to enhance physician education through self-study resources and learning technologies.

Torax Medical, Inc. is a clinical-stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters to treat various digestive diseases. Its primary offerings include LINX, a reflux management system designed for patients with gastroesophageal reflux disease (GERD), and FENIX, a continence restoration system for fecal incontinence. Utilizing specialized magnets, these devices facilitate minimally invasive procedures to address these conditions. Torax Medical operates in both the European and U.S. markets and is a subsidiary of Ethicon, Inc.

Tranzyme Pharma is a biopharmaceutical company based in North Carolina that specializes in the discovery, development, and commercialization of mechanism-based therapies. The company focuses on small molecule therapeutics aimed at treating acute and chronic gastrointestinal motility disorders. Tranzyme's product portfolio includes TZP-101, which is intended for the treatment of post-operative ileus and severe gastroparesis, as well as TZP-301, which targets obesity and metabolic syndrome. The company retains worldwide rights to its programs, emphasizing its commitment to addressing significant health challenges related to gastrointestinal conditions.

AxioMed LLC specializes in designing and developing disc replacement devices aimed at alleviating neck pain and restoring normal spinal functions for patients suffering from degenerative disc disease. Founded in 2001 and based in Malden, Massachusetts, the company was previously known as AxioMed Spine Corporation until its name change in 2014. AxioMed has developed the Freedom® Lumbar Disc and initiated clinical trials for its products, which are intended to improve the standard of care beyond traditional fusion and first-generation artificial discs. The company is led by CEO Patrick McBrayer and COO James Kuras, who oversee a team with extensive experience in spinal implants and engineering. They are supported by a Medical Advisory Panel of surgeons from prominent spine centers and universities. AxioMed's operations encompass product development, testing, clinical and regulatory affairs, and manufacturing, with ongoing projects focusing on cervical spine solutions.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Clarus Therapeutics is a men's health specialty pharmaceutical company based in Northbrook, Illinois, founded in 2003. The company specializes in the development and commercialization of oral testosterone replacement therapies in the United States. Its primary product, JATENZO, is a soft gel formulation of testosterone undecanoate, designed to treat men with low testosterone levels, also known as hypogonadism. JATENZO is notable for being the first and only oral testosterone replacement therapy available, serving as the sole source of revenue for Clarus Therapeutics. In addition to JATENZO, the company is also engaged in the development of other androgen-based medications for both men and women.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

OsteoBiologics is a biotechnology company. It engages in the development and manufacture of bio-absorbable polymeric scaffolds, films, and related instrumentations for the repair and replacement of bone, soft tissue, and articular cartilage. It provides ACTAEON, a tissue evaluation system, which determines the degree and scope of articular cartilage degeneration. It also manufactures custom parts. OsteoBiologics was founded in 1993 and is headquartered in San Antonio, Texas.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.